Longitudinal analysis of frequency and reactivity of epstein-barr virus-specific T lymphocytes and their association with intermittent viral reactivation

Journal of Medical Virology

Volumn 84, Issue 1, 2012, Pages 119-131

  Vogl, Bastian A ^a   Fagin, Ursula ^a   Nerbas, Linda ^a   Schlenke, Peter ^a   Lamprecht, Peter ^a   Jabs, Wolfram J ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

CD8 positive CTL; ELISPOT; Healthy carriers; HLA tetramers

Indexed keywords

GAMMA INTERFERON; HLA A2 ANTIGEN; HLA ANTIGEN CLASS 1;

ADULT; ALLELE; ARTICLE; BLOOD ANALYSIS; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; EPSTEIN BARR VIRUS; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LONGITUDINAL STUDY; LYMPHOBLASTOID CELL LINE; MALE; NONHUMAN; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; VIREMIA; VIRUS LOAD; VIRUS REACTIVATION;

ADULT; CD8-POSITIVE T-LYMPHOCYTES; ENZYME-LINKED IMMUNOSPOT ASSAY; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; FLOW CYTOMETRY; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; MALE; MIDDLE AGED; RECURRENCE; VIRUS ACTIVATION;

HUMAN HERPESVIRUS 4;

EID: 81355147244     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.22258     Document Type: Article

References (57)

1. Adhikary D, Behrends U, Moosmann A, Witter K, Bornkamm GW, Mautner J. 2006. Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins. J Exp Med 203: 995-1006.
2. Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JI, McMichael AJ, Davis MM. 1996. Phenotypic analysis of antigen-specific T lymphocytes. Science 274: 94-96.
3. Amon W, Farrell PJ. 2005. Reactivation of Epstein-Barr virus from latency. Rev Med Virol 15: 149-156.
4. Amyes E, Hatton C, Montamat-Sicotte D, Gudgeon N, Rickinson AB, McMichael AJ, Callan MF. 2003. Characterization of the CD4+ T cell response to Epstein-Barr virus during primary and persistent infection. J Exp Med 198: 903-911.
5. Annels NE, Kalpoe JS, Bredius RG, Claas EC, Kroes AC, Hislop AD, Baarle D, Egeler RM, van Tol MJ, Lankester AC. 2006. Management of Epstein-Barr virus (EBV) reactivation after allogeneic stem cell transplantation by simultaneous analysis of EBV DNA load and EBV-specific T cell reconstitution. Clin Infect Dis 42: 1743-1748.
6. Arora SK. 2002. Analysis of intracellular cytokines using flow cytometry. Methods Cell Sci 24: 37-40.
7. Bogedain C, Wolf H, Modrow S, Stuber G, Jilg W. 1995. Specific cytotoxic T lymphocytes recognize the immediate-early transactivator Zta of Epstein-Barr virus. J Virol 69: 4872-4879.
8. Brooks JM, Murray RJ, Thomas WA, Kurilla MG, Rickinson AB. 1993. Different HLA-B27 subtypes present the same immunodominant Epstein-Barr virus peptide. J Exp Med 178: 879-887.
9. Burrows SR, Sculley TB, Misko IS, Schmidt C, Moss DJ. 1990a. An Epstein-Barr virus-specific cytotoxic T cell epitope in EBV nuclear antigen 3 EBNA 3. J Exp Med 171: 345-349.
10. Burrows SR, Misko IS, Sculley TB, Schmidt C, Moss DJ. 1990b. An Epstein-Barr virus-specific cytotoxic T-cell epitope present on A- and B-type transformants. J Virol 64: 3974-3976.
11. Burrows SR, Gardner J, Khanna R, Steward T, Moss DJ, Rodda S, Suhrbier A. 1994. Five new cytotoxic T cell epitopes identified within Epstein-Barr virus nuclear antigen 3. J Gen Virol 75: 2489-2493.
12. Doisne JM, Urrutia A, Lacabaratz-Porret C, Goujard C, Meyer L, Chaix ML, Sinet M, Venet A. 2004. CD8+ T cells specific for EBV, cytomegalovirus, and influenza virus are activated during primary HIV infection. J Immunol 173: 2410-2418.
13. Gavioli R, Kurilla MG, de Campos-Lima PO, Wallace LE, Dolcetti R, Murray RJ, Rickinson AB, Masucci MG. 1993. Multiple HLA A11-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4. J Virol 67: 1572-1578.
14. Gratama JW, van Esser JW, Lamers CH, Tournay C, Lowenberg B, Bolhuis RL, Cornelissen JJ. 2001. Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. Blood 98: 1358-1364.
15. Gudgeon NH, Taylor GS, Long HM, Haigh TA, Rickinson AB. 2005. Regression of Epstein-Barr virus-induced B-cell transformation in vitro involves virus-specific CD8+ T cells as the principal effectors and a novel CD4+ T-cell reactivity. J Virol 79: 5477-5788.
16. Heller KN, Gurer C, Munz C. 2006. Virus-specific CD4+ T cells: Ready for direct attack. J Exp Med 203: 805-808.
17. Hess C, Means TK, Autissier P, Woodberry T, Altfeld M, Addo MM, Frahm N, Brander C, Walker BD, Luster AD. 2004. IL-8 responsiveness defines a subset of CD8 T cells poised to kill. Blood 104: 3463-3471.
18. Hill AB, Lee SP, Haurum JS, Murray N, Yao QY, Rowe M, Signoret N, Rickinson AB, McMichael AJ. 1995a. Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised. J Exp Med 181: 2221-2228.
19. Hill A, Worth A, Elliott T, Rowland-Jones S, Brooks J, Rickinson A, McMichael A. 1995b. Characterization of two Epstein-Barr virus epitopes restricted by HLA-B7. Eur J Immunol 25: 18-24.
20. Hislop AD, Annels NE, Gudgeon NH, Leese AM, Rickinson AB. 2002. Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection. J Exp Med 195: 893-905.
21. Hislop AD, Kuo M, Drake-Lee AB, Akbar AN, Bergler W, Hammerschmitt N, Khan N, Palendira U, Leese AM, Timms JM, Bell AI, Buckley CD, Rickinson AB. 2005. Tonsillar homing of Epstein-Barr virus-specific CD8+ T cells and the virus-host balance. J Clin Invest 115: 2546-2555.
22. Hornef MW, Bein G, Fricke L, Steinhoff J, Wagner HJ, Hinderer W, Sonneborn HH, Kirchner H. 1995. Coincidence of Epstein-Barr virus reactivation, cytomegalovirus infection, and rejection episodes in renal transplant recipients. Transplantation 60: 474-480.
23. Hudnall SD, Ge Y, Wei L, Yang NP, Wang HQ, Chen T. 2005. Distribution and phenotype of Epstein-Barr virus-infected cells in human pharyngeal tonsils. Mod Pathol 18: 519-527.
24. Ikeda T, Kobayashi R, Horiuchi M, Nagata Y, Hasegawa M, Mizuno F, Hirai K. 2000. Detection of lymphocytes productively infected with Epstein-Barr virus in non-neoplastic tonsils. J Gen Virol 81: 1211-1216.
25. Ikuta K, Satoh Y, Hoshikawa Y, Sairenji T. 2000. Detection of Epstein-Barr virus in salivas and throat washings in healthy adults and children. Microbes Infect 2: 115-120.
26. Jabs WJ, Hennig H, Kittel M, Pethig K, Smets F, Bucsky P, Kirchner H, Wagner HJ. 2001. Normalized quantification by real-time PCR of Epstein-Barr virus load in patients at risk for posttransplant lymphoproliferative disorders. J Clin Microbiol 39: 564-569.
27. Kerr BM, Kienzle N, Burrows JM, Cross S, Silins SL, Buck M, Benson EM, Coupar B, Moss DJ, Sculley TB. 1996. Identification of type B-specific and cross-reactive cytotoxic T-lymphocyte responses to Epstein-Barr virus. J Virol 70: 8858-8864.
28. Khanna R, Burrows SR. 2000. Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases. Annu Rev Microbiol 54: 19-48.
29. Khanna R, Burrows SR, Kurilla MG, Jacob CA, Misko IS, Sculley TB, Kieff E, Moss DJ. 1992. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: Implications for vaccine development. J Exp Med 176: 169-176.
30. Khanna R, Sherritt M, Burrows SR. 1999. EBV structural antigens, gp350 and gp85, as targets for ex vivo virus-specific CTL during acute infectious mononucleosis: Potential use of gp350/gp85 CTL epitopes for vaccine design. J Immunol 162: 3063-3069.
31. Laichalk LL, Thorley-Lawson DA. 2005. Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. J Virol 79: 1296-1307.
32. Lee SP, Thomas WA, Murray RJ, Khanim F, Kaur S, Young LS, Rowe M, Kurilla M, Rickinson AB. 1993. HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2. J Virol 67: 7428-7435.
33. Lee SP, Tierney RJ, Thomas WA, Brooks JM, Rickinson AB. 1997. Conserved CTL epitopes within EBV latent membrane protein 2: A potential target for CTL-based tumor therapy. J Immunol 158: 3325-3334.
34. Letsch A, Scheibenbogen C. 2003. Quantification and characterization of specific T-cells by antigen-specific cytokine production using ELISPOT assay or intracellular cytokine staining. Methods 31: 143-149.
35. Leung E, Shenton BK, Green K, Jackson G, Gould FK, Yap C, Talbot D. 2004. Dynamic EBV gene loads in renal, hepatic, and cardiothoracic transplant recipients as determined by real-time PCR light cycler. Transpl Infect Dis 6: 156-164.
36. Maurmann S, Fricke L, Wagner HJ, Schlenke P, Hennig H, Steinhoff J, Jabs WJ. 2003. Molecular parameters for precise diagnosis of asymptomatic Epstein-Barr virus reactivation in healthy carriers. J Clin Microbiol 41: 5419-5428.
37. McCurley TL, Larson R. 1996. Clinical applications of flow cytometry in hematology and immunology. Clin Lab Sci 9: 358-362.
38. Milosevic S, Behrends U, Adhikary D, Mautner J. 2006. Identification of major histocompatibility complex class II-restricted antigens and epitopes of the Epstein-Barr virus by a novel bacterial expression cloning approach. J Virol 80: 10357-10364.
39. Morgan SM, Wilkinson GW, Floettmann E, Blake N, Rickinson AB. 1996. A recombinant adenovirus expressing an Epstein-Barr virus (EBV) target antigen can selectively reactivate rare components of EBV cytotoxic T-lymphocyte memory in vitro. J Virol 70: 2394-2402.
40. Murray RJ, Kurilla MG, Brooks JM, Thomas WA, Rowe M, Kieff E, Rickinson AB. 1992. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): Implications for the immune control of EBV-positive malignancies. J Exp Med 176: 157-168.
41. Obel N, Hoier-Madsen M, Kangro H. 1996. Serological and clinical findings in patients with serological evidence of reactivated Epstein-Barr virus infection. APMIS 104: 424-428.
42. Pattle SB, Farrell PJ. 2006. The role of Epstein-Barr virus in cancer. Expert Opin Biol Ther 6: 1193-1205.
43. Payne DA, Mehta SK, Tyring SK, Stowe RP, Pierson DL. 1999. Incidence of Epstein-Barr virus in astronaut saliva during spaceflight. Aviat Space Environ Med 70: 1211-1213.
44. Preiksaitis JK, Diaz-Mitoma F, Mirzayans F, Roberts S, Tyrrell DL. 1992. Quantitative oropharyngeal Epstein-Barr virus shedding in renal and cardiac transplant recipients: Relationship to immunosuppressive therapy, serologic responses, and the risk of posttransplant lymphoproliferative disorder. J Infect Dis 166: 986-994.
45. Rickinson AB, Moss DJ. 1997. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol 15: 405-431.
46. Rooney CM, Rickinson AB, Moss DJ, Lenoir GM, Epstein MA. 1985. Cell-mediated immunosurveillance mechanisms and the pathogenesis of Burkitt's lymphoma. IARC Sci Publ 60: 249-260.
47. Saulquin X, Ibisch C, Peyrat MA, Scotet E, Hourmant M, Vie H, Bonneville M, Houssaint E. 2000. A global appraisal of immunodominant CD8 T cell responses to Epstein-Barr virus and cytomegalovirus by bulk screening. Eur J Immunol 30: 2531-2539.
48. Schaade L, Kleines M, Hausler M. 2001. Application of virus-specific immunoglobulin M (IgM), IgG, and IgA antibody detection with a polyantigenic enzyme-linked immunosorbent assay for diagnosis of Epstein-Barr virus infections in childhood. J Clin Microbiol 39: 3902-3905.
49. Spiegel HM, Ogg GS, DeFalcon E, Sheehy ME, Monard S, Haslett PA, Gillespie G, Donahoe SM, Pollack H, Borkowsky W, McMichael AJ, Nixon DF. 2000. Human immunodeficiency virus type 1- and cytomegalovirus-specific cytotoxic T lymphocytes can persist at high frequency for prolonged periods in the absence of circulating peripheral CD4(+) T cells. J Virol 74: 1018-1022.
50. Staege MS, Lee SP, Frisan T, Mautner J, Scholz S, Pajic A, Rickinson AB, Masucci MG, Polack A, Bornkamm GW. 2002. MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells. Proc Natl Acad Sci USA 99: 4550-4555.
51. Steven NM, Annels NE, Kumar A, Leese AM, Kurilla MG, Rickinson AB. 1997. Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response. J Exp Med 185: 1605-1617.
52. Terajima M, Cruz J, Raines G, Kilpatrick ED, Kennedy JS, Rothman AL, Ennis FA. 2003. Quantitation of CD8+ T cell responses to newly identified HLA-A*0201-restricted T cell epitopes conserved among vaccinia and variola (smallpox) viruses. J Exp Med 197: 927-932.
53. Tomkinson BE, Maziarz R, Sullivan JL. 1989. Characterization of the T cell-mediated cellular cytotoxicity during acute infectious mononucleosis. J Immunol 143: 660-670.
54. van Esser JW, van der Holt B, Meijer E, Niesters HG, Trenschel R, Thijsen SF, van Loon AM, Frassoni F, Bacigalupo A, Schaefer UW, Osterhaus AD, Gratama JW, Löwenberg B, Verdonck LF, Cornelissen JJ. 2001. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood 98: 972-978.
55. Wagner HJ, Fischer L, Jabs WJ, Holbe M, Pethig K, Bucsky P. 2002. Longitudinal analysis of Epstein-Barr viral load in plasma and peripheral blood mononuclear cells of transplanted patients by real-time polymerase chain reaction. Transplantation 74: 656-664.
56. Yao QY, Rickinson AB, Epstein MA. 1985. A re-examination of the Epstein-Barr virus carrier state in healthy seropositive individuals. Int J Cancer 35: 35-42.
57. Ye M, Kasey S, Khurana S, Nguyen NT, Schubert S, Nugent CT, Kuus-Reichel K, Hampl J. 2004. MHC class II tetramers containing influenza hemagglutinin and EBV EBNA1 epitopes detect reliably specific CD4(+) T cells in healthy volunteers. Hum Immunol 65: 507-513.